Skip to main content

Table 3 Results from multiple logistic regression analysis with Odds Ratios (OR) of factors affecting improved outcomes in the two groups HFpEF and HFrEF

From: Evaluation of the usefulness of EQ-5D as a patient-reported outcome measure using the Paretian classification of health change among patients with chronic heart failure

HFpEF ≥50%HFrEF < 40%
Clinic (cardiology vs. medicine/geriatric clinic)  1.428< 0.001
Fatigue (pronounced/severe limitations vs. light)  1.588< 0.001
Shortness of breath (pronounced/severe limitations vs. light)1.5960.005  
Ischaemic heart disease (yes/no)  0.7870.004
Pulmonary disease (yes/no)  0.7420.014
Reduced renal function (yes/no)0.7090.0370.712< 0.001
  1. All analyses controlled for: Sex (female vs. male), Age (over 75 years old), Smoker (yes/no), Clinic (Cardiology vs. Medicine/Geriatrics), Follow up referral to hospital (Hospital vs. Primary care) Follow up referral to out-patient HF nurse (yes/no), NYHA classification grades III/IV vs. 1/II, Fatigue – pronounced/severe limitations, Shortness of breath – pronounced/severe limitations, Duration of heart failure > 6 months), Ischaemic heart disease, Previous myocardial infarction, Hypertension, Atrial fibrillation/flutter, Diabetes, Pulmonary disease, Anaemia, Mean heart rate bpm > 70, Renal function (e-GFR < 60 μmol/L), ACEI/ARB, ß-blocker, MRA, Diuretic
  2. Abbreviations: ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, EF ejection fraction, e-GFR estimated glomerular filtration, HFrEF Heart Failure with Reduced Ejection Fraction, HFpEF Heart Failure with Preserved Ejection Fraction, MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association